ACADIA Pharmaceuticals Inc (ACAD.OQ)
ACAD.OQ on NASDAQ Stock Exchange Global Select Market
17.16USD
8:53pm IST
17.16USD
8:53pm IST
Change (% chg)
$1.33 (+8.40%)
$1.33 (+8.40%)
Prev Close
$15.83
$15.83
Open
$16.15
$16.15
Day's High
$17.46
$17.46
Day's Low
$16.15
$16.15
Volume
503,504
503,504
Avg. Vol
736,801
736,801
52-wk High
$41.20
$41.20
52-wk Low
$14.52
$14.52
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.45 | December | 19 Jun 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 1 | 1 | 1 | 1 |
| (2) OUTPERFORM | 6 | 6 | 6 | 6 |
| (3) HOLD | 1 | 1 | 1 | 1 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 2.00 | 2.00 | 2.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 7 | 59.24 | 60.30 | 57.00 | 41.96 |
| Quarter Ending Sep-18 | 7 | 70.81 | 73.93 | 66.00 | 47.30 |
| Year Ending Dec-18 | 7 | 261.41 | 271.60 | 254.87 | 216.53 |
| Year Ending Dec-19 | 8 | 421.44 | 466.27 | 311.00 | 407.11 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 7 | -0.45 | -0.41 | -0.47 | -0.57 |
| Quarter Ending Sep-18 | 7 | -0.40 | -0.34 | -0.45 | -0.54 |
| Year Ending Dec-18 | 7 | -1.67 | -1.50 | -1.97 | -2.05 |
| Year Ending Dec-19 | 8 | -0.66 | -0.21 | -1.11 | -0.79 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 46.26 | 48.87 | 2.61 | 5.64 |
| Quarter Ending Dec-17 | 44.32 | 43.56 | 0.76 | 1.71 |
| Quarter Ending Sep-17 | 32.03 | 35.58 | 3.55 | 11.08 |
| Quarter Ending Jun-17 | 20.02 | 30.48 | 10.46 | 52.24 |
| Quarter Ending Mar-17 | 15.19 | 15.29 | 0.09 | 0.61 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | -0.55 | -0.44 | 0.11 | -19.80 |
| Quarter Ending Dec-17 | -0.58 | -0.55 | 0.03 | -4.45 |
| Quarter Ending Sep-17 | -0.62 | -0.53 | 0.09 | -15.06 |
| Quarter Ending Jun-17 | -0.72 | -0.55 | 0.17 | -23.61 |
| Quarter Ending Mar-17 | -0.73 | -0.72 | 0.01 | -1.96 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 59.24 | 59.24 | 59.24 | 60.34 | 41.96 |
| Quarter Ending Sep-18 | 70.81 | 70.81 | 70.81 | 70.63 | 47.30 |
| Year Ending Dec-18 | 261.41 | 261.41 | 261.41 | 263.43 | 216.53 |
| Year Ending Dec-19 | 421.44 | 421.44 | 421.44 | 443.05 | 407.11 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.45 | -0.45 | -0.45 | -0.48 | -0.57 |
| Quarter Ending Sep-18 | -0.40 | -0.40 | -0.40 | -0.42 | -0.54 |
| Year Ending Dec-18 | -1.67 | -1.67 | -1.67 | -1.83 | -2.05 |
| Year Ending Dec-19 | -0.66 | -0.66 | -0.66 | -0.61 | -0.79 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Acadia Pharmaceuticals Q1 Loss Per Share $0.44
- BRIEF-Acadia Pharmaceuticals Says CEO Stephen Davis's FY 2017 Total Compensation Was $15.2 Mln
- FDA says reviewing Acadia's Parkinson's medication, shares fall
- FDA says reviewing Acadia's Parkinson's medication, shares fall
- BRIEF-Acadia Pharma Q4 Loss Per Share $0.55